Literature DB >> 36241933

Prescription appropriateness of anticoagulant drugs for prophylaxis of venous thromboembolism in hospitalized multimorbid older patients.

Raffaella Rossio1, Sara Mandelli2, Ilaria Ardoino2, Alessandro Nobili2, Flora Peyvandi1, Pier Mannuccio Mannucci3, Carlotta Franchi4.   

Abstract

The aims were to assess: the prescription prevalence of anticoagulant drugs for thromboprophylaxis (TP) in hospitalized older patients; the appropriateness of their prescription or non-prescription; the in-hospital mortality in appropriately versus non-appropriately prescribed or not prescribed patients. 4836 patients aged 65 or older, admitted to the Italian internal medicine and geriatric wards participating to the REPOSI register from 2012 to 2019 were assessed for prescription of anticoagulant drugs for TP at admission and/or during hospital stay. The Padua Prediction Score (PPS) and the IMPROVE score were used to assess the thrombotic and bleeding risk. Patients were considered to be appropriately prescribed when had PPS ≥ 4 and IMPROVE < 7, and appropriately not prescribed when PPS < 4. Logistic regression model was used to assess whether appropriateness was associated with in-hospital mortality. Among 4836 patients included, anticoagulants were prescribed for TP in 1233 (25.5%). In all, 4461 patients were assessable for appropriateness: 3136 (70.3%) were appropriately prescribed or non-prescribed according to their thrombotic and bleeding risk. Among 1138 patients receiving prophylaxis, only 360 (31.7%) were appropriately prescribed, while among 3323 non-prescribed patients, 2776 (83.5%) were appropriately non-prescribed. The in-hospital mortality rate was lower in patients appropriately prescribed or non-prescribed than in those inappropriately prescribed or non-prescribed (OR: 0.63; 95% CI: 0.46-0.83). In conclusion, a high prevalence of multimorbid hospitalized patients were appropriately prescribed or non-prescribed for TP with anticoagulants, appropriate non-prescription being mainly driven by a high bleeding risk. The appropriateness of prescription or non-prescription was associated with lower in-hospital mortality.
© 2022. The Author(s), under exclusive licence to Società Italiana di Medicina Interna (SIMI).

Entities:  

Keywords:  Anticoagulant; Appropriateness of drug prescription; Elderly; Internal medicine; Thromboprophylaxis

Year:  2022        PMID: 36241933     DOI: 10.1007/s11739-022-03121-7

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN: 1828-0447            Impact factor:   5.472


  18 in total

1.  Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE investigators.

Authors:  Hervé Decousus; Victor F Tapson; Jean-François Bergmann; Beng H Chong; James B Froehlich; Ajay K Kakkar; Geno J Merli; Manuel Monreal; Mashio Nakamura; Ricardo Pavanello; Mario Pini; Franco Piovella; Frederick A Spencer; Alex C Spyropoulos; Alexander G G Turpie; Rainer B Zotz; Gordon Fitzgerald; Frederick A Anderson
Journal:  Chest       Date:  2010-05-07       Impact factor: 9.410

2.  Changes in clinical outcomes for community-dwelling older people exposed to incident chronic polypharmacy: a comparison between 2001 and 2009.

Authors:  Carlotta Franchi; Maura Marcucci; Pier Mannuccio Mannucci; Mauro Tettamanti; Luca Pasina; Ida Fortino; Angela Bortolotti; Luca Merlino; Alessandro Nobili
Journal:  Pharmacoepidemiol Drug Saf       Date:  2015-12-21       Impact factor: 2.890

3.  Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Susan R Kahn; Wendy Lim; Andrew S Dunn; Mary Cushman; Francesco Dentali; Elie A Akl; Deborah J Cook; Alex A Balekian; Russell C Klein; Hoang Le; Sam Schulman; M Hassan Murad
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 4.  Venous thrombosis in the elderly: incidence, risk factors and risk groups.

Authors:  M J Engbers; A van Hylckama Vlieg; F R Rosendaal
Journal:  J Thromb Haemost       Date:  2010-10       Impact factor: 5.824

5.  A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score.

Authors:  S Barbar; F Noventa; V Rossetto; A Ferrari; B Brandolin; M Perlati; E De Bon; D Tormene; A Pagnan; P Prandoni
Journal:  J Thromb Haemost       Date:  2010-11       Impact factor: 5.824

Review 6.  Venous thromboembolism in the elderly: A narrative review.

Authors:  T Tritschler; D Aujesky
Journal:  Thromb Res       Date:  2017-05-17       Impact factor: 3.944

7.  Medication adherence in community-dwelling older people exposed to chronic polypharmacy.

Authors:  Carlotta Franchi; Ilaria Ardoino; Monica Ludergnani; Gjiliola Cukay; Luca Merlino; Alessandro Nobili
Journal:  J Epidemiol Community Health       Date:  2021-01-26       Impact factor: 3.710

8.  American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients.

Authors:  Holger J Schünemann; Mary Cushman; Allison E Burnett; Susan R Kahn; Jan Beyer-Westendorf; Frederick A Spencer; Suely M Rezende; Neil A Zakai; Kenneth A Bauer; Francesco Dentali; Jill Lansing; Sara Balduzzi; Andrea Darzi; Gian Paolo Morgano; Ignacio Neumann; Robby Nieuwlaat; Juan J Yepes-Nuñez; Yuan Zhang; Wojtek Wiercioch
Journal:  Blood Adv       Date:  2018-11-27

9.  Combined assessment of thrombotic and haemorrhagic risk in acute medical patients.

Authors:  Micaela La Regina; Francesco Orlandini; Francesca Marchini; Alessia Marinaro; Rosanna Bonacci; Paola Bonanni; Francesca Corsini; Anna Maria Ceraudo; Edoarda Pacetti; Lucia Scuotri; Davide Costabile; Francesco Dentali
Journal:  Thromb Haemost       Date:  2015-09-24       Impact factor: 5.249

10.  Pattern of in-hospital changes in drug use in the older people from 2010 to 2016.

Authors:  C Franchi; I Ardoino; A Nobili; L Pasina; P M Mannucci; A Marengoni; F Perticone
Journal:  Pharmacoepidemiol Drug Saf       Date:  2017-10-13       Impact factor: 2.890

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.